98%
921
2 minutes
20
Background: Spatial heterogeneity of prostate cancer-specific mortality in Pennsylvania remains unclear. We utilized advanced geospatial survival regressions to examine spatial variation of prostate cancer-specific mortality in PA and evaluate potential effects of individual- and county-level risk factors.
Methods: Prostate cancer cases, aged ≥40 years, were identified in the 2004-2014 Pennsylvania Cancer Registry. The 2018 County Health Rankings data and the 2014 U.S. Environmental Protection Agency's Environmental Quality Index were used to extract county-level data. The accelerated failure time models with spatial frailties for geographical correlations were used to assess prostate cancer-specific mortality rates for Pennsylvania and by the Penn State Cancer Institute (PSCI) 28-county catchment area. Secondary assessment based on estimated spatial frailties was conducted to identify potential health and environmental risk factors for mortality.
Results: There were 94,274 cases included. The 5-year survival rate in PA was 82% (95% confidence interval, CI: 81.1-82.8%), with the catchment area having a lower survival rate 81% (95% CI: 79.5-82.6%) compared to the non-catchment area rate of 82.3% (95% CI: 81.4-83.2%). Black men, uninsured, more aggressive prostate cancer, rural and urban Appalachia, positive lymph nodes, and no definitive treatment were associated with lower survival. Several county-level health (i.e., poor physical activity) and environmental factors in air and land (i.e., defoliate chemical applied) were associated with higher mortality rates.
Conclusions: Spatial variations in prostate cancer-specific mortality rates exist in Pennsylvania with a higher risk in the PSCI's catchment area, in particular, rural-Appalachia. County-level health and environmental factors may contribute to spatial heterogeneity in prostate cancer-specific mortality.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7203834 | PMC |
http://dx.doi.org/10.1186/s12885-020-06902-5 | DOI Listing |
Adv Urol
August 2025
Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Yamaguchi, Japan.
In biochemically recurrent prostate cancer (BRPC), no definitive independent prognostic factors were reported. This study aimed to identify the factors impacting overall survival (OS) in patients with BRPC after radical prostatectomy (RP). Among 610 consecutive patients who underwent RP between January 2000 and December 2019, with follow-up through December 2024, 152 (25%) patients who developed BRPC were analyzed.
View Article and Find Full Text PDFUrol Oncol
September 2025
Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada.
Objective: To examine differences in cancer-specific mortality (CSM) in nonmetastatic upper tract urothelial carcinoma (UTUC) patients with vs. without secondary bladder cancer (BCa) after radical nephroureterectomy (RNU).
Methods: Within the Surveillance, Epidemiology, and End Results database (SEER 2000-2021), T1-T4N0M0 UTUC patients treated with RNU and diagnosed with secondary BCa were identified.
Purpose: Perineural invasion (PNI) and lymphovascular invasion (LVI) represent tumor escape mechanisms at radical prostatectomy (RP). We assessed their prognostic significance for biochemical recurrence (BCR) following complete resection.
Methods: We analyzed 10,471 men with negative surgical margins after RP, stratified into three groups based on pathological PNI and LVI status: Group 1 (PNI-/LVI-, n = 1,925), Group 2 (PNI+/LVI-, n = 7,849), and Group 3 (LVI+, n = 697; 14 with PNI-/LVI + and 683 with PNI+/LVI+).
Int J Urol
September 2025
Division of Urology, Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan.
Objectives: The efficacy of local therapy for oligometastatic prostate cancer has been increasingly reported; however, there is little evidence regarding the treatment of patients with castration-resistant disease compared with that for those with castration-sensitive disease. In this retrospective study, we examined data of patients with oligoprogressive castration-resistant prostate cancer (CRPC) treated with progressive site-directed therapy (PSDT) and investigated the prognosticators of treatment efficacy.
Methods: The cohort comprised 35 patients with oligoprogressive CRPC who underwent radiotherapy in the form of PSDT.
HRB Open Res
August 2025
Department of General Practice, Royal College of Surgeons in Ireland (RCSI), Dublin, Ireland.
Background: Cancer is a leading cause of mortality in Ireland, accounting for approximately 30% of deaths annually. Early diagnosis improves survival, reduces treatment burden, and enhances patient outcomes. Rapid Access Clinics (RACs) were introduced to facilitate expedited diagnosis of suspected lung, prostate, and breast cancers, as well as malignant melanoma.
View Article and Find Full Text PDF